← Back to signals
BIIB
BUYBiogen Inc.
Health Care
0.83
PEGY ratio
Rank #127
Why This Matters
This stock appears undervalued relative to its growth and dividend yield. Strong projected growth of 78.4% annually over 5 years.
BIIB trades at 20.7x earnings against 25.0% capped growth (actual 78.4%) (no dividend) (PEGY 0.83). Valuation looks favorable — the price is not fully reflecting the growth and yield on offer.
~ Growth estimate uses historical CAGR (forward estimates unavailable)
- • Growth rate derived from historical CAGR — limited analyst coverage.
- • Growth rate capped at 25% for PEGY calculation (actual: 78.4%). Per Peter Lynch methodology, growth above 25% is rarely sustainable over 5 years.
Scan date: 2026-06-02
Valuation
20.7x
P/E Ratio
Growth
78.4%
5yr EPS
Income
0.0%
Div Yield
PEGY Components
PEGY Score0.83
Denominator25.0%
EPS (TTM)$9.30
Market Data
Price$192.23
ExchangeNASDAQ
S&P 500Nasdaq 100
What Changed
PEGY Score
0.83→0.83(-0.01)
Rank
#124→#127(3 positions)
vs 7 days ago
Portfolio Context
Founder does not hold this stock.
Not in your portfolio.
Sector: Health Care
PEGY History — 90 days
Data: Yahoo Finance • Updated nightly 11 PM ET • For informational purposes only